Sinli Tate Lipatin listed for sale once a week long-acting preparation is being clinically

Recently, Xinlitai injection with recombinant Tripapeptide (commodity name: Xin Futai) began to sell, retail price of 960 yuan / box (10 bottles / box, 200 IU / 20 sg / bottle), the amount of 1 bottle per day, the annual treatment cost of about 35,000 yuaninjection with tripapeptide (recombinant parathyroid 1-34 (rhPTH1-34) freeze-dried powder needle), is a heavy-duty drug developed by Lilly in the field of osteoporosis treatment, the commodity compound io, is currently approved by the FDA to promote bone formation of the drugLilly's 2019 results show that Futaio's global sales were $1.4 billion , down 11 percent from a year earlierFutaio was approved in 2011 in China, due to high pricing, corporate promotion and other factors did not achieve high returns, Insight database shows that the current original research in the country's latest winning bid of 5338.50 yuan (20 ?g: 80 sl, 2.4 ml / branch), according to the use of the instructions for the use of the annual treatment costs of about 686,000 yuan, and not included in the medical insurance, for ordinary patients is still expensiveSeptember 29, 2019, Xinlitai's recombinant Tripa peptide was approved by the State Drug Administration, and the conditionation of the disease was the treatment of postmenopausal women with high risk of fractures, becoming the second domestic approved enterprise (the first approved domestic enterprise is Shanghai United Searle)At present, Shanghai United Searle's domestic winning bid of 202.93 yuan / bottle, Xinlitai currently has an absolute pricing advantagein addition, insight database shows that the current recombinant Tripapeptide once-a-week long-acting powder needle form is currently under way clinical trials (clinical registration number: CTR20181346)The pharmacokinetics, safety and efficacy of the treatment of postmenopausal osteoporosis in postmenopausal women were evaluated by using two doses and supporting data for Phase III clinical trials using two doses and through 24 weeks of continuous treatment of recombinant parathyroidin (1-34) (G56W1) for the treatment of postmenopausal osteoporosisimage source: Insight database (https://db.dxy.cn)injection recombinant Tripartate (Xin Futai) for The first listed biological products of Xinlitai, further enriching the company's product type, while filling the company's gaps in the field of orthopaedics;original title: Xinlitai "Tripa peptide" retail price of 96 yuan / bottle (about 35,000 / year), once a week long-acting preparation is being clinical